Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of lacosamide for uncontrolled primary generalized tonic-clonic seizures in idiopathic generalized epilepsy
2014-004375-23Phase 2
- Sponsor
- UCB
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lacosamide in idiopathic epilepsy (IGE) and primary generalized tonic-clonic seizure (PGTCS), sponsored by UCB. Primary endpoint: Treatment-emergent adverse events.
02
Drugs
lacosamide
03
Conditions
idiopathic epilepsy (IGE)primary generalized tonic-clonic seizure (PGTCS)
Beyond the preview
Go deeper on 2014-004375-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004375-23.